基本信息
浏览量:3
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
The research of Kirk J. Wangensteen focuses on defining genetic factors involved in liver disease progression and the development of liver cancer. The goal of his research program is to make clinical impacts by improving the understanding of disease biology and by developing new therapeutics.
Lab projects incorporate early discovery using genetic screens in mice livers, mechanistic work to identify gene function and regulation of genetic pathways. Other endeavors involve collaborative work to apply genetic tools for gene delivery and screening, as well as human subjects research to identify genetic associations for liver diseases in patients.
One current research project in the Wangensteen lab is based on results from a genetic screen to identify genes that can accelerate or inhibit liver regeneration. Through this screening process, the lab discovered a gene that is required for liver hepatocytes to divide in response to severe liver injury. Yet the same gene is dispensable for normal liver development and homeostasis. The team also discovered that the gene is required for cancer to form. It may be possible to target this gene for cancer prevention in settings with an inherent elevated risk of cancer, such as in cirrhosis.
Focus areas
Characterizing genetic pathways involved in liver repopulation and homeostasis. The Wangensteen lab uses a mouse model of liver injury and repopulation that repeats many features of liver disease that occur in patients. This model enables the disruption of gene function in many genes using a parallel genetic assay with a CRISPR-Cas9 system that Dr. Wangensteen and colleagues engineered. Through genetic screens, the lab identifies novel mechanisms of liver regeneration and potential targets for therapy.
Identifying targets to treat or prevent liver cancer. The Wangensteen lab performs genetic screens in mice to systematically target gene expression levels to better understand how genes cooperate to drive cancer. His team is working to identify tumor-intrinsic gene pathways that the immune system recognizes.
Genetic association studies in patients with liver cancer. Dr. Wangensteen leads a multidisciplinary team that is studying whether patients with liver cancer harbor genetic variants that are associated with cancer risk.
Lab projects incorporate early discovery using genetic screens in mice livers, mechanistic work to identify gene function and regulation of genetic pathways. Other endeavors involve collaborative work to apply genetic tools for gene delivery and screening, as well as human subjects research to identify genetic associations for liver diseases in patients.
One current research project in the Wangensteen lab is based on results from a genetic screen to identify genes that can accelerate or inhibit liver regeneration. Through this screening process, the lab discovered a gene that is required for liver hepatocytes to divide in response to severe liver injury. Yet the same gene is dispensable for normal liver development and homeostasis. The team also discovered that the gene is required for cancer to form. It may be possible to target this gene for cancer prevention in settings with an inherent elevated risk of cancer, such as in cirrhosis.
Focus areas
Characterizing genetic pathways involved in liver repopulation and homeostasis. The Wangensteen lab uses a mouse model of liver injury and repopulation that repeats many features of liver disease that occur in patients. This model enables the disruption of gene function in many genes using a parallel genetic assay with a CRISPR-Cas9 system that Dr. Wangensteen and colleagues engineered. Through genetic screens, the lab identifies novel mechanisms of liver regeneration and potential targets for therapy.
Identifying targets to treat or prevent liver cancer. The Wangensteen lab performs genetic screens in mice to systematically target gene expression levels to better understand how genes cooperate to drive cancer. His team is working to identify tumor-intrinsic gene pathways that the immune system recognizes.
Genetic association studies in patients with liver cancer. Dr. Wangensteen leads a multidisciplinary team that is studying whether patients with liver cancer harbor genetic variants that are associated with cancer risk.
研究兴趣
论文共 96 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Gastroenterologyno. 5 (2024): S-681
Perapa Chotiprasidhi, Karina Sato Espinoza, Jun Ma,Yvonne Nartey,Yaw Awuku,Adwoa Agyei-Nkansah,Mary Afihene,Amoako Duah,Sally Bampoh, Shadrack Asibey,Joshua Ayawin,Jun Wang,
Journal of Hepatology (2024)
Kelsey S. Lau-Min,Joseph Bleznuck,Colin Wollack,Danielle B. McKenna,Jessica M. Long, Anna P. Hubert, Mariah Johnson,Shavon E. Rochester,Gillain Constantino,Christina Dudzik,Abigail Doucette,Kirk Wangensteen,
Gastroenterologyno. 7 (2023): 1279-1292
ACS applied materials & interfacesno. 18 (2023): 21877-21892
Gastroenterology (2023)
JAMA network openno. 6 (2023): e2320222-e2320222
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn